Jiangsu Recbio Technology Co., Ltd. has established itself as a pioneering force in the vaccine industry through the development of three innovative platforms: a novel adjuvant platform, a protein engineering platform, and an immunological evaluation platform. The novel adjuvant platform allows Recbio to create new adjuvants that enhance immune responses beyond traditional aluminum-based adjuvants, enabling the company to independently develop vaccines that can effectively target high-burden infectious diseases. The protein engineering platform employs a structure-based approach to optimize antigens, utilizing various expression systems such as E. coli, Hansen's yeast, baculovirus, and CHO cells. This versatility facilitates the rapid identification and development of vaccine candidates, including those for HPV and COVID-19.

The immunological evaluation platform is crucial for understanding the immune mechanisms associated with emerging infectious diseases. It enables Recbio to select optimal combinations of antigens and adjuvants to enhance immunogenicity. With a strong scientific foundation, the company has been able to conduct advanced immunological tests, such as fake virus neutralization and ELISPOT assays, which are integral to their vaccine development process. Collectively, these platforms position Recbio as a leader in innovative vaccine research and development, with a robust pipeline of products aimed at addressing significant public health challenges.

China

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial and has a leading research and development progress. Apart from that, ReCOV, a recombinant COVID-19 vaccine, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market.

Cancer

Infectious Diseases

Skin Diseases

Urogenital Diseases

Jiangsu Recbio Technology

COVID-19

ReCOV (Recombinant COVID-19 Vaccine)

Biologics

Vaccines

Human Papillomavirus

REC603

REC601 (Recombinant HPV Bivalent Vaccine, Type 16/18)

REC602 (Recombinant HPV Bivalent Vaccine, Type 6/11)

Shingles

REC610 (Recombinant Shingles Vaccine)

REC604a (2nd Gen. Recombinant HPV Quadrivalent Vaccine)

REC604b (2nd Gen. Recombinant HPV 9-valent Vaccine)

R520A (mRNA COVID-19 Vaccine)

Gene Therapy

Tuberculosis

REC607 (Sendai Virus Vector Vaccine)

REC606 (Recombinant TB Vaccine)

Influenza

REC617 (Recombinant Influenza Quadrivalent Vaccine)

Hand, Foot, and Mouth Disease

REC605 (Recombinant HFMD Quadrivalent Vaccine)

RNA Therapies

Therapeutic

Jiangsu Recbio Technology

Company Details